CD79A and inflammatory bowel disease: measured the IgG and IgA production against the receptor binding domain (RBD) of the SARS-CoV-2 spike, full-length spike (S) and the nucleocapsid (N) in patients with IBD and SARS-CoV-2 infection treated with either infliximab or vedolizumab monotherapy, or infliximab/thiopurine combination therapy (50).